CRN welcomes greater flexibility in FDA's final NDI guidance, calls for clarity on outstanding regulatory questions
“CRN urges FDA to prioritize addressing these fundamental issues to provide the regulatory certainty necessary to support responsible innovation and consumer access to safe dietary supplements.”